BrightPath Biotherapeutics Co., Ltd.
4594.T
Price:
$50
Market Cap:
$4.63B
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody t...[Read more]
Industry
Biotechnology
IPO Date
2015-10-22
Stock Exchange
JPX
Ticker
4594.T
PE Ratio
[-4.33]
ROE
[-97.87%]
Current Ratio
[12.43]
Dividend Yield
[0%]
Enterprise Value
[3.72B]
Dividend History
The ROE as of December 2025 (TTM) for BrightPath Biotherapeutics Co., Ltd. (4594.T) is -97.87%
According to BrightPath Biotherapeutics Co., Ltd.’s latest financial reports and current stock price. The company's current ROE is -97.87%. This represents a change of 289.07% compared to the average of -25.16% of the last 4 quarters.
BrightPath Biotherapeutics Co., Ltd. (4594.T) Historical ROE (quarterly & annually)
How has 4594.T ROE performed in the past?
The mean historical ROE of BrightPath Biotherapeutics Co., Ltd. over the last ten years is -62.08%. The current -97.87% ROE has changed 57.65% with respect to the historical average. Over the past ten years (40 quarters), 4594.T's ROE was at its highest in in the June 2016 quarter at -5.07%. The ROE was at its lowest in in the September 2015 quarter at -73.71%.
Average
-62.08%
Median
-53.02%
Minimum
-124.45%
Maximum
-21.42%
BrightPath Biotherapeutics Co., Ltd. (4594.T) ROE by Quarter and Year
Discovering the peaks and valleys of BrightPath Biotherapeutics Co., Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 62.96%
Maximum Annual ROE = -21.42%
Minimum Annual Increase = -41.41%
Minimum Annual ROE = -124.45%
| Year | ROE | Change |
|---|---|---|
| 2025 | -124.45% | 4.30% |
| 2024 | -119.32% | 25.89% |
| 2023 | -94.77% | 61.65% |
| 2022 | -58.63% | 20.61% |
| 2021 | -48.61% | -15.35% |
| 2020 | -57.42% | 55.30% |
| 2019 | -36.98% | 62.96% |
| 2018 | -22.69% | 5.95% |
| 2017 | -21.42% | -41.41% |
| 2016 | -36.55% | -9.24% |
BrightPath Biotherapeutics Co., Ltd. (4594.T) Average ROE
How has 4594.T ROE performed in the past?
The current ROE of BrightPath Biotherapeutics Co., Ltd. (4594.T) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-112.85%
5-year avg
-89.16%
10-year avg
-62.08%
BrightPath Biotherapeutics Co., Ltd. (4594.T) ROE vs. Peers
How is 4594.T’s ROE compared to its peers?
BrightPath Biotherapeutics Co., Ltd.’s ROE is greater than ADR120S, Inc. (-133.55%), greater than OncoTherapy Science, Inc. (-90.96%), greater than K Pharma,Inc. (-40.16%), greater than Noile-Immune Biotech Inc. (-15.03%), greater than TMS Co., Ltd. (-23.94%), greater than PRISM BioLab Co.,LTD (-40.67%), greater than Linical Co., Ltd. (-8.74%), greater than Chiome Bioscience Inc. (-62.16%), less than Kohjin Bio Co., Ltd. (12.85%), greater than MedRx Co., Ltd (-65.52%),
| Company | ROE | Market cap |
|---|---|---|
| -133.55% | $7.44B | |
| -90.96% | $7.11B | |
| -40.16% | $7.43B | |
| -15.03% | $6.97B | |
| -23.94% | $6.10B | |
| -40.67% | $6.51B | |
| -8.74% | $6.82B | |
| -62.16% | $7.55B | |
| 12.85% | $7.96B | |
| -65.52% | $6.53B |
Build a custom stock screener for BrightPath Biotherapeutics Co., Ltd. (4594.T) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BrightPath Biotherapeutics Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
BrightPath Biotherapeutics Co., Ltd. (4594.T) and other stocks custom spreadsheet templates
The easiest way to analyze a company like BrightPath Biotherapeutics Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is BrightPath Biotherapeutics Co., Ltd.'s ROE?
How is the ROE calculated for BrightPath Biotherapeutics Co., Ltd. (4594.T)?
What is the highest ROE for BrightPath Biotherapeutics Co., Ltd. (4594.T)?
What is the 3-year average ROE for BrightPath Biotherapeutics Co., Ltd. (4594.T)?
What is the 5-year average ROE for BrightPath Biotherapeutics Co., Ltd. (4594.T)?
How does the current ROE for BrightPath Biotherapeutics Co., Ltd. (4594.T) compare to its historical average?